<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63802">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275312</url>
  </required_header>
  <id_info>
    <org_study_id>A-92-52120-192</org_study_id>
    <nct_id>NCT02275312</nct_id>
  </id_info>
  <brief_title>ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity</brief_title>
  <acronym>ETREAT</acronym>
  <official_title>ETREAT Study: A Prospective Observational Study to Evaluate the Effectiveness of Botulinum Toxin Type A (BoNT-A) Injections in Patients With Post-stroke Upper and/or Lower Limb Spasticity in the Early Stage of Spasticity Development.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effectiveness of BoNT-A on functional
      improvement in patients with post-stroke upper and/or lower limb spasticity in the early
      stage of spasticity development, according to routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Goal Attainment Scale (GAS) score.</measure>
    <time_frame>Baseline, 16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spasticity patterns will be defined in patients with upper and/or lower limb spasticity in the early stage after stroke</measure>
    <time_frame>Baseline, 16 months</time_frame>
    <description>Descriptive statistics will be presented in addition to 95% confidence intervals for the mean and percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Ashworth Scale (MAS) score.</measure>
    <time_frame>Baseline, 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline characteristics of patients</measure>
    <time_frame>Baseline</time_frame>
    <description>Demographic characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reporting functional improvement evaluated by Goal Attainment Scale (GAS) score.</measure>
    <time_frame>From baseline up to 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain according to Visual Analog Scale (VAS).</measure>
    <time_frame>Baseline, 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Passive function of upper and/or lower limbs according to primary treatment target (PTT) from the disability assessment scale (DAS).</measure>
    <time_frame>Baseline, 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfortable barefoot walking speed, measured with the 10-meter walking speed test.</measure>
    <time_frame>Baseline, 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on EQ-5D quality of life questionnaire</measure>
    <time_frame>Baseline, 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of use of healthcare resources and costs associated with management of spasticity.</measure>
    <time_frame>From baseline up to 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval between injections</measure>
    <time_frame>From baseline up to 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost per patient</measure>
    <time_frame>From baseline up to 16 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">112</enrollment>
  <condition>Spasticity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Post-stroke spasticity
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18-80 years.

          -  Poststroke limb spasticity.

          -  Patients who have suffered a stroke in the previous 6 months.

          -  Treatment goal has been previously agreed with the patient or their legal
             representative.

          -  Patients with clinically significant poststroke upper/lower limb spasticity, in whom
             it has been decided to perform multidisciplinary treatment with BoNT-A +
             rehabilitation.

          -  No previous treatment with BoNT-A.

          -  Patient is able to follow the protocol.

          -  Written informed consent.

        Exclusion Criteria:

          -  Neuromuscular disease.

          -  Use of drugs that interfere with neuromuscular transmission.

          -  Any other condition that could interfere with rehabilitation or evaluation of the
             results.

          -  Diagnosis of spasticity not associated with stroke.

          -  Pregnant or nursing mothers.

          -  Prior participation in any other study in the 6 months before study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Garcia Pascual</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canarias</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guipúzcoa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>October 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
